Phar­ma vet Va­le­ria Fan­tin jumps to on­col­o­gy team at Gilead; João Sif­fert out as Abeona looks for an­oth­er CEO

→ News broke on Twit­ter yes­ter­day that Va­le­ria Fan­tin has head­ed to Gilead to be their VP, on­col­o­gy re­search, a field in which CEO Dan O’Day has placed par­tic­u­lar em­pha­sis with the $21 bil­lion ac­qui­si­tion of Im­munomedics.

The well-trav­eled bio­phar­ma ex­ec just com­plet­ed a brief run as CSO at Zai Lab and has al­so been CSO at ORIC Phar­ma­ceu­ti­cals. Fan­tin, who start­ed out in epi­ge­net­ics and ki­nase drug dis­cov­ery at Mer­ck in 2004, then moved to ARI­AD Phar­ma­ceu­ti­cals in 2008, on­ly to quick­ly piv­ot to Agios Phar­ma­ceu­ti­cals not long af­ter its in­cep­tion as a mol­e­c­u­lar on­col­o­gy di­rec­tor. Af­ter Agios, she was VP, tu­mor cell bi­ol­o­gy at Pfiz­er, help­ing de­vel­op Ibrance and dis­cov­er Lor­bre­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.